Infection, Human Immunodeficiency Virus
Conditions
Keywords
HIV, HLA-B*5701, Abacavir hypersensitivity reaction, HIV Infection
Brief summary
This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B\*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction. The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin. They will be asked to give two samples to test for the presence of the genetic marker HLA-B\*5701. The two samples are: * A cheek swab * A blood sample In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B\*5701 testing.
Interventions
PROCEDURECheek swab & blood test
Cheek swab & blood test
Sponsors
GlaxoSmithKline
ViiV Healthcare
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-1 infected patients over 18 years of age * Patient willing & able to understand and provide written informed consent
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of HLA-B*5701 in the UK population via central labs | 2 Hours | The widespread of HLA-B\*5701 applied in the selected area in each participant of the UK population was tested via central labs. The result is summarized here. |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of HLA-B*5701 in major UK ethnotypes in the study population. | 2 Hours |
| Description of HLA-B*5701 in the UK population via local labs. | 2 Hours |
Countries
United Kingdom
Outcome results
None listed